Expert Panel on TACE and TARE for HCC: Weighing the Pros and Cons

Integrity CE

M. Pishvaian, R. Salem

Updates in Combination Therapy for HCC

Yale Cancer Center

S. Stein

Understanding HCC: Perspectives on Diagnosis, Risk Factors, and Trea…

Yale Cancer Center

A. Jaffe

Expert Panel on Choosing Systemic vs. Locoregional Therapy in HCC

Integrity CE

M. Pishvaian, A. Singal, R. Finn, R. Salem

ASCO® GI 2024 Summary: "HCC Key Studies Including EMERALD-1 & IMbrav…

Insights from 2024 ASCO® GI Annual Meeting

R. Kim, T. Biachi

GI Oncology Year in Review: Hepatobiliary Cancers

Yale Cancer Center

P. Kunz

Management of Toxicity and Dose Modification Associated With Cabozan…

Cedars Sinai

J. Gong

Hepatic Arterial Infusion for Primary Liver Cancer

Integrity CE

K. Lafaro

ACG 2023 Highlights: HCC Updates - Diagnosis and Management

ACG 2023 Conference Coverage

R. Wong

How to Incorporate Molecular Testing in Therapy for Localized Cholan…

Flavio Rocha

Year in Review: Gastric, Esophageal, & Liver Cancers

OncoAlert

S. Gill

Systemic Treatment Landscape for Advanced HCC: Case Discussion - 40 …

The France Foundation

A. Burgoyne, S. Stein

Mixed HCC-Cholangiocarcinoma: Case Presentation and Panel Discussion

Integrity CE

M. Nakazawa, J. Harding, C. Shubert, J. Birkness-Gartman, M. Yarchoan

Advancements in Systemic Therapy for Advanced HCC: Where Are We Going

Johns Hopkins

M. Yarchoan

Treatment Approaches in Bone Metastases Pain Management

Francesco Massari

ASCO® 2023 Insights: "Randomized, Double-Blind, Placebo-Controlled D…

Insights from 2023 ASCO® Annual Meeting

A. Batra

Combining Locoregional and Systemic Therapy for Challenging HCC Cases

The France Foundation

R. Avritscher, A. O. Kaseb

Common TKI Toxicity Management in 2L HCC Treatment

NYU Langone

J. Wu

Considerations for 1L Treatment Selection in Advanced HCC: Safety an…

Yale Cancer Center

S. Stein

ASCO GI 2023 NRG/RTOG 1112 Randomized Phase 3 Study: Sorafenib vs. S…

ASCO GI 2023 Conference Coverage

L. Dawson